Are you a Physician?
Home
Home

Inquiry Form

open

A clinical trial designed specifically for patients with Alport syndrome

CARDINAL is a Phase 2/3 clinical study
evaluating the safety and effectiveness of bardoxolone methyl
(an oral investigational drug) for the treatment of Alport syndrome.
Up to 210 participants will be enrolled in CARDINAL at approximately
60 research centers around the world.


You may be eligible for this study if you:
Are 12 to 60 years of age l Have been genetically diagnosed with Alport syndrome
(if genetic testing is needed, the cost is covered by Reata)
Other eligibility criteria will apply.

To see if you pre-qualify for CARDINAL

 

The following information is for health care professionals (HCP) only. If you are an HCP, please click YES below to proceed. If you are not an HCP but would like more information, click NO and you will proceed to the home page for additional study information or you can email CARDINAL@reatapharma.com